Titlebook: Comparative Effectiveness in Surgical Oncology; Key Questions and Ho Karl Y. Bilimoria,Christina A. Minami,David M. Mah Book 2015 Springer

上漲

Comparative Effectiveness Research for Sarcoma,rvival, quality of life and cost-effectiveness of care, the current state of the art is summarized. Specialized/regional care for sarcoma and the utility of tumor boards or multispecialty discussion is discussed. Issues related to treatment efficacy and sequencing in relation to chemotherapy, radiat

豐滿中國

詞匯

驚惶

Comparative Effectiveness Issues in Lung Cancer,ity of cancer care, and the need for care of the growing number of cancer survivors, comparative effectiveness research opportunities will continue to emerge for this disease. In this chapter, we focus on CER opportunities in lung cancer surgery from the vantage point of those factors directly influ

聽覺

詼諧

Research Gaps in Pancreatic Cancer Research and Comparative Effectiveness Research Methodologies,ith late stage disease, and approximately 6?% of patients are alive 5?years after diagnosis. Of the 10–20?% of patients who are candidates for resection and multi-modality therapy, most will succumb to the disease with 5-year survival rates only reaching approximately 25?% (Lim et al. in Annals of s

怎樣才咆哮

Comparative Effectiveness in Hepatic Malignancies,reases both in the United States and worldwide, accurate analysis of which tests and treatments should be applied in which situations is critical, both in terms of measurable and meaningful clinical outcomes and health care costs. In the last 20?years alone, multiple controversies have arisen in the

因無茶而冷淡

Comparative Effectiveness Research in Urologic Cancers,ed. In this chapter, we examine the three most common urologic malignancies: Prostate cancer, kidney cancer, and bladder cancer. We will review progress made in comparative effectiveness research for each cancer and outline important topics where future research is needed.

BARGE

Comparative Effectiveness Research in Gynecologic Oncology,ance therapeutic efficacy and toxicity of treatment, how to individualize therapy to particular patients or groups of patients, and how to contain the rapidly rising costs associated with oncologic care. In this chapter we examine three common and highly debated clinical scenarios in gynecologic onc

irritation

Book 2015rue for the surgical management of solid-organ malignancies. Comparative effectiveness is a relatively new term which encompasses the age-old concepts of how best to treat cancer patients. Comparative effectiveness is defined as the direct comparison of healthcare interventions to determine which wo